FGFR3

[hgh_29]

any info if any FGFR3 inhibitors show any effect for the craniofacial structure


also in ur opinion

which would be more effective in this sense

Erdafitinib or Pemigatinib

 

[TakaTeo]

neither, you should be asking what governs craniofacial development in a normal individual past adolescence rather than which oncology drug inhibits a receptor that was never pathologically overactive in the first place , go onto Google scholar and READ

 

[hgh_29]

still an adolescence rn

 

[exsttttt]

any info if any FGFR3 inhibitors show any effect for the craniofacial structure


also in ur opinion

which would be more effective in this sense

Erdafitinib or Pemigatinib

for craniofacial structure fgfr2 inhibition is more significant than 3